NFKB1 and osteoporosis: Pristimerin’s regulatory effect on both PI3K and NF-κB pathways appears similar to that of SR, although its anti-inflammatory action is more pronounced, making it beneficial in inflammatory and estrogen-deficient osteoporosis (Xu et al., 2022).